Norpace Cr — Competitive Intelligence Brief

Norpace Cr (DISOPYRAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

marketed Antiarrhythmic Histamine H1 receptor Cardiovascular Small molecule

Target snapshot

Norpace Cr (DISOPYRAMIDE) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norpace Cr TARGET	DISOPYRAMIDE	Pfizer	marketed	Antiarrhythmic	Histamine H1 receptor	1977-01-01
Lastacaft	ALCAFTADINE	AbbVie	marketed	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Elestat	EPINASTINE	AbbVie	marketed	Adrenergic Receptor Agonist	Histamine H1 receptor	2003-01-01
Rupax	RUPATADINE	Teikoku Seiyaku	marketed	rupatadine	Histamine H1 receptor	2001-01-01
Zaditor	KETOTIFEN		marketed	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1999-01-01
Mizollen	MIZOLASTINE	Sanofi	marketed	mizolastine	Histamine H1 receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic class)

1. Pfizer · 3 drugs in this class
2. National Taiwan University Hospital · 2 drugs in this class
3. Boehringer Ingelheim · 1 drug in this class
4. Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
5. Eli Lilly · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Technical University of Munich · 1 drug in this class
8. · 1 drug in this class
9. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
10. Ain Shams University · 1 drug in this class